Here are five key notes about the acquisition:
1. CD Diagnostics CEO Rick Birkmeyer told Delaware Online that the startup will be staying in Delaware.
2. CD Diagnostics will become Zimmer Biomet’s diagnostic division. Mr. Birkmeyer will continue to run this division as Zimmer Biomet’s vice president.
3. Zimmer Biomet invested $3 million into the startup when it was founded in 2012. Zimmer Biomet also handled marketing for CD Diagnostics’ first product, Synovasure.
4. Synovasure is a hand-held device that diagnoses infections from joint replacement surgery. The devices are already sold in Western Europe, however, CD Diagnostics is awaiting approval from the FDA before introducing the product in the United States.
5. Mr. Birkmeyer told Delaware Online that, moving forward, CD Diagnostics is developing tests for osteopathic arthritis.
More articles on orthopedics:
Mayo Clinic researchers find causal link between senescent cells and osteoarthritis: 3 insights
Christus St. Elizabeth Hospital and Beaumont Bone and Joint Institute launch joint replacement program: 4 key points
Dr. Matthew Bennett joins the UHS Pain Management team: 3 things to know
